NCT07176351View on ClinicalTrials.gov

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Opioid Use Disorder

Interventions

DRUG

Buprenorphine

Weekly or monthly extended-release subcutaneous injection

Trial Locations (1)

06520

Yale School of Medicine, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Braeburn Inc

UNKNOWN

lead

Yale University

OTHER